GSK acquires stake in Swiss BioVersys

(CercleFinance.com) - Swiss biopharmaceutical company BioVersys announced on Tuesday that the British healthcare giant is to take a stake in its capital as part of a strengthening of their strategic collaboration in the treatment of tuberculosis.


Under the terms of the agreement, GSK will subscribe 12.3m Swiss francs (around E12.6m) to the company's latest Series C financing for a total of 44.9m Swiss francs.

The group also plans to deepen its collaboration with BioVersys, which specializes in the development of new antibiotic treatments to combat bacterial resistance.

In particular, it plans to support the development of BVL-GSK098, a small molecule currently in Phase 2a trials for the treatment of multi-drug-resistant pulmonary tuberculosis, one of the ten most deadly infections worldwide, causing 1.3 million deaths a year.

GSK and BioVersys say they want to make their new treatment available to patients 'as quickly as possible'.


Copyright (c) 2024 CercleFinance.com. All rights reserved.